Source Fact: Financial Supervisory Service DART / 2024-06-25
Disclosure Type: Conclusion of Single Sales/Supply Contract
💡 3-Second Summary
Samsung Biologics has officially executed a definitive formal contract manufacturing organization (CMO) agreement worth approximately KRW 211.5B (USD 152.17M) with Kiniksa Pharmaceuticals (UK), Ltd, converting a prior Letter of Intent (LOI) initiated in May 2023 into a finalized supply contract.
📊 1. [Summary of Core Disclosure & Key Figures]
- Contract Name: Contract Manufacturing Agreement (Pharmaceuticals)
- Contract Amount: KRW 211,468,250,378 (Fixed amount: USD 152,168,274)
- Applied FX Rate: KRW 1,389.70 per USD (Based on the initial standard proxy rate on June 25, 2024)
- Ratio to Recent Sales: 5.72% of the 2023 consolidated annual revenue (KRW 3.69T)
- Counterparty: Kiniksa Pharmaceuticals (UK), Ltd
- Contract Period: June 21, 2024 ~ December 31, 2031 (A long-term deal spanning roughly 7 years and 6 months)
- Execution (Order) Date: June 25, 2024
- Note: This agreement represents the execution of the definitive formal contract corresponding to the “Major Management Matters Related to Investment Judgment” previously disclosed on May 30, 2023. There is no disclosure withholding applied, leaving the client identity fully transparent.
📈 2. [Expert Insight: Implications for Investors]
- Formalization of Revenue Pipeline: The transition from a preliminary corporate tracking phase into a formal single sales/supply contract structures the projected backlog into finalized operational schedules. This serves as a positive indicator for the company’s mid-to-long-term Fundamental by anchoring visible revenue streams.
- Securing Long-Term Asset Utilization: With the contract runway extending until late 2031, this long-term agreement secures production continuity over multiple years. It is likely to exert a supportive impact on stabilizing asset utilization metrics across active production lines.
- Investor Consideration: Because the contract value is fixed in USD (approx. USD 152.17M), the final realized revenue denominated in KRW remains subject to fluctuations based on real-time exchange rate trends at the time of future delivery. Additionally, as explicitly noted in the filing, the contract expiration timeline remains subject to potential adjustments based on mutual agreements between both parties.
📝 Editor’s Comment (by K-STOCK Editor)
A legacy framework tracking line has successfully cross-converted into a fully definitive supply milestone. This filing establishes a KRW 211.5 billion commercial framework representing 5.72% of annual sales with UK-based Kiniksa Pharmaceuticals, signaling that operational integration is now moving full steam ahead. Securing a manufacturing window through 2031 enhances long-term baseline visibility for plant capacity allocation. Notably, the lack of any confidentiality placeholders provides clear transparency for market participants tracking the company’s real-time commercial portfolio. Moving forward, shareholders should monitor real-time FX pacing during the invoicing phases to evaluate its final 원화 conversion impacts.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
